Chemoimmunotherapy for advanced gastrointestinal carcinomas: A successful combination of gene therapy and cyclophosphamide

The combination of a single low dose of cyclophosphamide (Cy) with the adenovirus-mediated gene transfer of interleukin-12 (AdIL-12) might represent a successful therapy for experimental gastrointestinal tumors. This approach has been proven to revert immunosuppressive mechanisms elicited by cancer cells and to synergistically promote antitumor immunity. In addition, this therapeutic regimen has been shown to be more efficient in achieving complete tumor regressions in mice than the application of a metronomic schedule of Cy plus AdIL-12.

Palabras clave: Chemoimmunotherapy , Gastrointestinal carcinomas , Interleukin-12 , Cyclophosphamide

Ver el registro completo

Archivos asociados

Tamaño: 372.5Kb

Formato: PDF

Descargar

Licencia

Excepto donde se diga explícitamente, este item se publica bajo la siguiente descripción: Creative Commons Attribution-NonCommercial-ShareAlike 2.5 Unported (CC BY-NC-SA 2.5)

Identificadores

URI: http://hdl.handle.net/11336/244904

URL: https://www.tandfonline.com/doi/abs/10.4161/onci.21651

DOI: http://dx.doi.org/10.4161/onci.21651

Colecciones

Articulos(CCT - ROSARIO)
Articulos de CTRO.CIENTIFICO TECNOL.CONICET - ROSARIO

Articulos(SEDE CENTRAL)
Articulos de SEDE CENTRAL

Citación

Malvicini, Mariana; Piccioni, Flavia Valeria; Bayo Fina, Juan Miguel; Fiore, Esteban Juan; Atorrasagasti, María Catalina; et al.; Chemoimmunotherapy for advanced gastrointestinal carcinomas: A successful combination of gene therapy and cyclophosphamide; Taylor & Francis; OncoImmunology; 1; 9; 12-2012; 1626-1628

Altmétricas